secwatch.observer — SEC 8-K summary
======================================

Issuer:     Blueprint Medicines Corp (—)
CIK:        0001597264
Form:       8-K
Filed at:   2025-07-18T23:59:59+00:00
Accession:  0001193125-25-160804
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi closes $9.1B acquisition of Blueprint Medicines; shares delisted
-----------------------------------------------------------------------

- Purchaser accepted 45,991,262 shares (70.9% of outstanding) at $129/share cash plus one CVR per share.
- Aggregate consideration ~$9.1B in cash plus CVRs with potential up to $6/share contingent on milestones.
- All directors resigned; Michael J. Tolpa became sole director; Blueprint now indirect Sanofi subsidiary.
- Shares no longer listed on Nasdaq; company will file Form 15 to suspend SEC reporting obligations.
- Previously disclosed stockholder litigation (Taylor action) resolved with $150,000 mootness fee; case closed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1597264/000119312525160804/0001193125-25-160804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1597264/000119312525160804/d909980d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-160804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer